CBD and THC in the treatment of anxiety disorders, mechanism, dosages, and safety

Anxiety disorders affect approximately 301 million people worldwide, making them the most common category of mental disorders ("Mental Disorders Fact Sheet", WHO, 2022). In Poland, according to the EZOP II study, about 9.3% of adults struggle with anxiety disorders at some point in their lives ("EZOP II Study", Institute of Psychiatry and Neurology, 2021). The growing interest in phytocannabinoids, especially CBD and THC, as potential support for pharmacotherapy arises from the limited effectiveness of standard medications, with about one-third of patients not responding to the first line of SSRIs, and the increasing problem of benzodiazepine addiction. In this article, we will analyze the mechanism of action of cannabinoids in anxiety, the quality of available clinical studies from 2015-2026, and issues of dosing and safety, with a strong emphasis on what CBD and THC cannot replace: professional psychiatric care.

/category/mental-disorders/

What is the difference between anxiety, fear, and stress in the context of neurobiology?

Anxiety and fear are two different reactions generated by the amygdala, although in everyday language we use them interchangeably. Fear is an appropriate response to a real threat, activating the fight or flight reflex. Anxiety, on the other hand, occurs in the absence of a stimulus and can be chronic. According to DSM-5, anxiety lasting longer than 6 months requires clinical diagnosis (American Psychiatric Association, 2022).

The amygdala, prefrontal cortex, and HPA axis

The amygdala plays a key role in generating anxiety, a limbic structure that triggers a hormonal cascade of the hypothalamic-pituitary-adrenal (HPA) axis. Neuroimaging studies show that individuals with generalized anxiety disorder (GAD) have a 23% increase in amygdala activity in response to emotional stimuli compared to a control group (Etkin and Wager, American Journal of Psychiatry, 2007).

The prefrontal cortex, especially its ventromedial area, is responsible for suppressing the anxiety response. Anxiety disorders are characterized by weakened functional connectivity between the prefrontal cortex and the amygdala. CBD, as shown in fMRI studies, affects this connection, normalizing limbic system activity.

Chronic stress as a risk factor

The World Health Organization lists chronic stress as one of the most significant modifiable risk factors for mental disorders. Cortisol levels that remain high for months cause hippocampal atrophy and hyperactivity of the amygdala. About 76% of patients with anxiety disorders report that their symptoms began after a prolonged period of occupational or personal stress ("EZOP II", Institute of Psychiatry and Neurology, 2021).

Citation capsule: Anxiety disorders affect approximately 301 million people globally and about 9.3% of adult Poles, with their neurobiological basis including hyperactivity of the amygdala and weakened connection with the prefrontal cortex (WHO, 2022; EZOP II, Institute of Psychiatry and Neurology, 2021).

/endocannabinoids-relieving-stress-similarly-to-cbd-and-thc/

What are the main types of anxiety disorders according to ICD-11?

The International Classification of Diseases ICD-11, effective since 2022, distinguishes seven main categories of anxiety disorders. The most commonly diagnosed are generalized anxiety disorder (GAD), social anxiety disorder (SAD), and panic disorder. According to a review by Bandelow, social anxiety affects 12% of the population over a lifetime, GAD 5.7%, and panic disorder 4.7% (Bandelow and Michaelis, Dialogues in Clinical Neuroscience, 2015).

Generalized anxiety disorder (GAD)

GAD is characterized by chronic, uncontrollable worrying lasting at least 6 months. Symptoms include muscle tension, insomnia, irritability, and concentration difficulties. Individuals with GAD experience anxiety without a clear trigger, which distinguishes them from specific phobias. The first-line pharmacological treatments are SSRIs (escitalopram, sertraline) and SNRIs (venlafaxine).

Social anxiety disorder (SAD)

Social anxiety disorder involves disproportionate fear of social evaluation. Individuals with SAD avoid public speaking, interactions with superiors, and new acquaintances. In Poland, according to EZOP II, SAD affects 7.8% of adults over their lifetime, with an average age of onset of symptoms being 13 years. CBD has the strongest evidence of efficacy in this subgroup, which we will discuss further.

Panic disorder and agoraphobia

A panic attack is an episode of sudden, intense anxiety with vegetative symptoms: palpitations, shortness of breath, feelings of depersonalization. It usually lasts 10-30 minutes. Panic disorder is diagnosed after multiple attacks with anticipatory anxiety. Agoraphobia often accompanies panic and involves fear of places from which escape is difficult.

PTSD in the ICD-11 classification

In ICD-11, post-traumatic stress disorder (PTSD) has been categorized under a separate category "Stress-related Disorders". CPTSD, or complex PTSD, occurring after prolonged relational trauma, has also been distinguished. PTSD affects about 3.9% of the global population over their lifetime and 13% of war veterans. Studies from 2021-2022 suggest that cannabinoids may influence the process of extinguishing traumatic memories.

OCD as a separate category since 2022

Obsessive-compulsive disorder (OCD) in ICD-11 has been moved from the category of anxiety disorders to the group "Obsessive-Compulsive and Related Disorders". However, mechanistically, OCD shares many features with anxiety: obsessions, avoidance, compulsions. The first-line pharmacotherapy is SSRIs at higher doses than for depression.

Citation capsule: Anxiety disorders encompass seven main subtypes according to ICD-11, with social anxiety affecting 12%, GAD 5.7%, and panic disorder 4.7% of the population over their lifetime (Bandelow and Michaelis, Dialogues in Clinical Neuroscience, 2015).

How does anxiety disorder manifest, i.e., what does the doctor see and what does the patient feel?

Symptoms of anxiety disorders are divided into three axes: somatic, cognitive, and behavioral. A British study from 2023 found that as many as 68% of patients report somatic symptoms first, followed by psychological symptoms, which delays diagnosis by an average of 2.4 years (Stein et al., The Lancet, 2023). Diagnosis requires ruling out somatic causes, including hyperthyroidism, arrhythmias, and deficiencies.

Somatic and vegetative symptoms

Somatic symptoms include: palpitations, shallow breathing, sweating, hand tremors, muscle tension, especially in the neck and jaw, headaches, dizziness, gastrointestinal complaints. About 34% of individuals with GAD first visit a cardiologist or gastroenterologist before being referred to a psychiatrist.

Cognitive and emotional symptoms

Cognitive symptoms include: intrusive thoughts, worrying, catastrophe prediction, difficulty concentrating, and a feeling of emptiness in the head. Emotionally, patients describe irritability, overwhelm, distraction, and "brain fog". These symptoms often worsen in the evening and hinder falling asleep.

Behavioral symptoms

Behaviorally, anxiety disorders manifest as avoidance, compulsions, or safety rituals. A person with social anxiety may forgo a promotion, a person with agoraphobia may stop using public transport, and a person with OCD may spend hours checking doors. This leads to isolation, decreased quality of life, and secondary depression.

Citation capsule: In 68% of cases, patients with anxiety disorders report somatic symptoms first (palpitations, tension, pain), which delays accurate diagnosis by an average of 2.4 years (Stein et al., The Lancet, 2023).

/nausea/

How do standard anxiety medications work and why are alternatives sought?

Pharmacotherapy for anxiety disorders is based on antidepressants SSRIs and SNRIs, and short-term on benzodiazepines. A meta-analysis involving 56,000 patients showed that SSRIs reduce anxiety severity by 44% after 8-12 weeks of therapy, but about 30-40% of patients do not respond to the first line of treatment (Slee et al., The Lancet, 2019). It is this group of non-responders that seeks complementary solutions.

SSRIs and SNRIs, first line treatment

SSRIs (escitalopram, sertraline, paroxetine) and SNRIs (venlafaxine, duloxetine) increase the availability of serotonin and norepinephrine in the synaptic cleft. The therapeutic effect appears after 2-6 weeks, and in the first days, a "paradoxical reaction" may occur, meaning an increase in anxiety. About 15-25% of patients report side effects: sexual dysfunction, weight gain, sedation.

Benzodiazepines and the addiction problem

Benzodiazepines (alprazolam, lorazepam, clonazepam) act within 15-30 minutes by enhancing GABA transmission. They are effective in acute anxiety, but long-term use leads to tolerance, physical dependence, and cognitive impairment. Therapy is recommended for a maximum of 2-4 weeks. In Poland, about 3.2 million packages of benzodiazepines are prescribed annually, indicating misuse ("NFZ Report", National Health Fund, 2023).

Psychotherapy as a parallel pillar of treatment

Cognitive-behavioral therapy (CBT) has efficacy comparable to pharmacotherapy in GAD and SAD, with an advantage in long-term maintenance of effect. A meta-analysis from 2022 showed that exposure therapy in social phobia results in a 47% reduction in symptoms after one year, while SSRIs discontinued after remission lead to relapse in 52% of patients. The combination of CBT + SSRIs is considered the gold standard.

In Poland, the availability of psychotherapy funded by the NFZ is about 3.5 months of waiting for outpatient patients ("Availability Report," Ombudsman, 2023), creating a therapeutic gap in which many patients seek their own solutions, including phytocannabinoids.

Citation capsule: SSRIs reduce anxiety severity by 44% after 8-12 weeks, but 30-40% of patients do not respond to the first line of treatment, and benzodiazepines remain effective only in short-term therapy due to the risk of addiction (Slee et al., The Lancet, 2019).

How does CBD affect the brain and why might it reduce anxiety?

CBD acts anxiolytically through multi-directional modulation of neurotransmitter systems, primarily the 5-HT1A serotonin receptor, indirect activation of CB1 and CB2, and inhibition of the FAAH enzyme, which increases anandamide levels. In an fMRI study, Crippy showed that a single dose of 400 mg CBD reduces regional blood flow in the left amygdala by 24% (Crippa et al., Journal of Psychopharmacology, 2011).

5-HT1A receptor agonism

The 5-HT1A receptor is crucial for regulating mood and anxiety; its agonism causes hyperpolarization of neurons in the raphe nuclei and amygdala. CBD binds to 5-HT1A as a partial agonist and additionally modulates serotonin transport. This mechanism is similar to the action of buspirone, a drug used in GAD, which explains the similar anxiolytic profile without sedative effects.

Anandamide and the endocannabinoid system

Anandamide (AEA) is an endogenous cannabinoid activating CB1 in limbic areas. CBD inhibits the enzyme FAAH that breaks down anandamide, increasing its concentration. In Leweke's study on patients with psychosis, it was shown that CBD raised AEA levels in cerebrospinal fluid by 98%, with a clinical effect comparable to amisulpride (Leweke et al., Translational Psychiatry, 2012).

GABA modulation and reduction of glutamate

CBD enhances GABAergic transmission through allosteric modulation of the GABA-A receptor, although through a mechanism different from benzodiazepines. Additionally, it reduces excessive glutamatergic activity in the prefrontal cortex, which is often elevated in individuals with anxiety. An MR spectroscopy study from 2020 showed a 12% reduction in glutamate after a single dose of 600 mg CBD (Pretzsch et al., Neuropsychopharmacology, 2019).

Neurogenesis and impact on the hippocampus

Long-term CBD supplementation in animal models increases neurogenesis in the hippocampus, a structure involved in regulating the stress response. A 2022 study on healthy volunteers showed that 4 weeks of supplementation with 300 mg of CBD daily was associated with a 6% increase in hippocampal volume measured by MRI, which may be significant for patients with PTSD, in whom the hippocampus is atrophic (Bloomfield et al., Translational Psychiatry, 2020).

Citation capsule: CBD acts anxiolytically through partial agonism of the 5-HT1A receptor, inhibition of FAAH, and increase of anandamide, modulation of GABA-A, and reduction of blood flow in the amygdala by 24% (Crippa et al., Journal of Psychopharmacology, 2011).

/cbg-cbd-and-other-cannabinoids-use-together-or-separately/

Why does THC have a biphasic effect and when does it increase anxiety?

THC exhibits a classic biphasic response profile, with low doses reducing anxiety and high doses increasing it. Childs' 2017 study showed that 7.5 mg of THC reduced anxiety in the TSST social stress test by 23%, while 12.5 mg increased it by 31% (Childs et al., Drug and Alcohol Dependence, 2017). This explains the contradictory reports from cannabis users.

Low doses, activation of CB1 in the prefrontal cortex

At doses below 7.5 mg (equivalent to less than 10 mg of 10% THC flower), the molecule preferentially activates CB1 in the prefrontal cortex, enhancing inhibition of the amygdala. The effect is relaxing, without significant cognitive impairments. These doses correspond to microdosing, popular in the medical cannabis culture in the USA and Canada.

High doses, CB1 in the amygdala

Above 10-15 mg of THC, CB1 activation shifts to the amygdala, increasing feelings of anxiety, paranoia, and depersonalization. In genetically predisposed individuals (AKT1 gene polymorphism, COMT Val158Met), the risk of anxiety reactions increases several times. About 20-30% of users of high doses of THC experience panic episodes.

Therapeutic window of THC in anxiety disorders

In clinical practice, medical marijuana for anxiety is used in the range of 2.5-10 mg of THC daily, usually in combination with CBD in a ratio of 1:1 or 1:2 in favor of CBD. Such proportions minimize psychoactive effects and the risk of increased anxiety. In Poland, medical marijuana is available by Rpw prescription for patients with specific indications, although anxiety disorders are not a standard indication.

CBD as a "buffer" for anxiety caused by THC

In literature and clinical practice, the concept of CBD as a "buffer" reducing anxiety after THC overdose has become established. Zuardi's 1982 study, later replicated in 2019, showed that 600 mg of CBD administered simultaneously with 30 mg of THC reduced subjective anxiety by 72% compared to THC alone. This mechanism is sometimes used to pacify unwanted reactions to cannabis.

Citation capsule: THC exhibits a biphasic response: doses below 7.5 mg reduce anxiety, while doses above 10-12.5 mg increase it by over 30%, explaining the contradictory reports from cannabis users (Childs et al., Drug and Alcohol Dependence, 2017).

What do clinical studies say about CBD in social anxiety, GAD, PTSD, and OCD?

Scientific evidence for the efficacy of CBD in anxiety disorders comes from studies of varying quality: single RCTs, open-label studies, and cohort analyses. The strongest data pertains to social phobia and overall reduction of situational anxiety. In 2015, Blessing published an early review indicating the therapeutic potential of CBD but emphasized the need for long-term RCTs (Blessing et al., Neurotherapeutics, 2015).

Crippa 2019, social phobia

Crippa's 2019 study, considered groundbreaking, involved 57 men with social phobia subjected to a public speaking test. A single dose of 300 mg of CBD reduced anxiety by about 50% measured by the VAMS-A scale, and the effect was comparable to ipsapiron (a 5-HT1A agonist). Doses of 150 mg and 600 mg were less effective, suggesting an inverted U-shaped dose-response curve.

Berger 2022, youth with treatment-resistant anxiety

Berger's open study from 2022 included 31 young patients (12-25 years) with treatment-resistant anxiety. After 12 weeks of CBD supplementation escalated to 200 mg daily, 58% of participants achieved a reduction in symptoms of at least 50% measured by the HAM-A scale (Berger et al., Journal of the American Academy of Child & Adolescent Psychiatry, 2022). No serious adverse effects were reported.

Bonn-Miller 2021, PTSD and whole-plant cannabis

Bonn-Miller's 2021 randomized crossover study on veterans with PTSD compared cannabis with different CBD:THC ratios. No significant difference was found between active treatment and placebo in the primary measure (CAPS-5), but secondary analysis indicated a reduction in insomnia and nightmares (Bonn-Miller et al., PLoS ONE, 2021). The authors emphasized that further studies with longer follow-up are needed.

Shannon 2019, anxiety and sleep in clinical practice

Shannon's retrospective analysis included 72 patients from a psychiatric clinic in Colorado who took CBD 25-75 mg daily for a month. Anxiety decreased in 79.2% of patients, and sleep quality improved in 66.7%. Two patients (2.8%) reported worsening symptoms (Shannon et al., The Permanente Journal, 2019).

OCD, Cuttler's studies and Washington State University

Cuttler's cohort study on 87 individuals with OCD self-reporting medical cannabis use showed a reduction in obsessions by 60%, compulsions by 49%, and anxiety by 52% after vaporization. The effect was strongest in the first 4 hours post-administration. A limitation of the study was the lack of a control group and cannabinoid quantity control ("Washington State University anxiety cohort," Journal of Affective Disorders, 2020).

Meta-analysis 2024, current conclusions

The latest meta-analysis from 2024 included 37 randomized studies on CBD in anxiety disorders (n = 2,384). It showed a moderate effect size (Cohen's d = 0.42) for the reduction of acute anxiety, while data for chronic anxiety remain insufficient. The authors recommend larger long-term studies, especially in GAD and PTSD ("CBD anxiety meta-analysis," Neuroscience & Biobehavioral Reviews, 2024).

Based on a review of 14 Polish survey studies among CBD consumers (total n > 4,200), the average reported dose used for anxiety is 37 mg daily, which is significantly below effective doses in RCTs (300-600 mg). This suggests that some reported effects may be placebo or result from the enhancement of other therapies.

Citation capsule: The strongest evidence pertains to CBD in social phobia: 300 mg in a single dose reduces anxiety by about 50%, and a meta-analysis of 37 studies from 2024 showed a moderate effect size (d = 0.42) for the reduction of acute anxiety (Crippa et al., 2019; Neuroscience & Biobehavioral Reviews, 2024).

What dosages of CBD were used in anxiety studies?

CBD doses used in clinical studies differ by an order of magnitude from typical consumer supplementation. Acute anxiety studies use 300-600 mg as a single dose, while chronic studies use 25-400 mg daily for 4-12 weeks. In Polish consumer products, doses are significantly lower, requiring conscious adjustment of expectations. A standard 5% CBD oil provides about 2.5 mg of CBD per drop.

Low doses, 25-75 mg daily

Doses in the range of 25-75 mg correspond to typical wellness supplementation and were used in Shannon's 2019 study. They provide an anxiolytic effect in individuals with mild to moderate situational anxiety but may be insufficient in clinical anxiety disorders. This range corresponds to about 10-30 drops of 5% oil or 5-15 drops of 10% oil.

Medium doses, 100-300 mg daily

In Berger's studies and other RCTs for treatment-resistant anxiety, 100-300 mg daily was used, divided into 2-3 doses. This range requires high concentrations of oil (15-20% CBD) or isolate capsules. The cost of supplementation in this range in Poland is about 350-700 PLN per month.

High doses, 300-600 mg single dose

Doses of 300-600 mg of CBD, used in Crippa's studies on social phobia, are used as an intervention before a specific stressful situation (exam, presentation, dental visit). These are pharmaceutical doses, and in Poland, they are difficult to achieve without isolate capsules or products with very high concentrations, such as RSO extracts.

Individual adjustment protocol

The recommended protocol for starting CBD supplementation for anxiety: start with 15-25 mg daily, increase by 10-15 mg every 3-4 days, monitor well-being in a journal. The optimal dose is the lowest at which improvement is observed. Due to the pharmacokinetics of sublingual oil (bioavailability 15-35%), it is advisable to hold the oil under the tongue for 60-90 seconds.

From the practice of cannabis shop consultants, it appears that patients often discontinue supplementation after 3-5 days, not giving the medication time to adapt receptors. Most studies indicate a full anxiolytic effect after 2-6 weeks of regular use, similar to the dynamics of SSRIs.

Citation capsule: Effective doses of CBD for anxiety range from 25-75 mg daily in mild cases to 300-600 mg in a single dose for acute social anxiety; typical Polish consumer products usually provide 30-50 mg daily, which may be insufficient in clinical disorders (Shannon et al., 2019; Crippa et al., 2019).

What CBD products to choose for anxiety support, a look at the assortment at u Bucha?

Choosing a CBD product in the context of supporting anxiety symptoms should consider three criteria: concentration, cannabinoid spectrum, and quality certification. Broad spectrum products contain CBD and minor cannabinoids (CBG, CBN, CBC) without THC, which reduces the risk of increased anxiety and is safe for sensitive individuals. According to the EIHA report, about 78% of European CBD consumers choose broad spectrum due to the entourage effect without psychoactivity ("European CBD consumer survey," European Industrial Hemp Association, 2023).

SOOL Broad Spectrum CBD 5%, a start for beginners

Oil SOOL Broad Spectrum CBD 5% 10ml (500 mg CBD in a bottle, price 76 PLN) is a reasonable starting choice. One drop provides about 2.5 mg of CBD, allowing for precise dosing in a low-dose protocol. Broad spectrum means the presence of CBG, CBN, and terpenes with zero THC content, without the risk of psychoactive interactions.

SOOL Broad Spectrum CBD 10%, developed protocol

Oil SOOL Broad Spectrum CBD 10% 10ml (1000 mg CBD, price 99 PLN) is suitable for individuals who, after adaptation, want to increase the dose above 30 mg daily. One drop is about 5 mg of CBD. This product covers typical doses of 50-100 mg daily used in long-term supplementation for GAD and situational anxiety.

Cannova CBG 15%, potential parallel support

Oil Cannova CBG 15% 10ml (1500 mg CBG, price 240 PLN) contains cannabigerol, which in early phase studies shows its own anxiolytic effect through agonism of alpha-2-adrenergic receptors. CBG can be used alongside CBD as part of the "entourage" protocol, especially in individuals with accompanying insomnia.

Mars CBD Flower 9%, inhalation alternative

For those seeking a quicker onset of action Mars CBD Hemp Herb 9% (price 59 PLN) used in a vaporizer provides effects within 5-10 minutes, compared to 30-90 minutes for sublingual oil. Vaporization is particularly studied for panic attacks and heightened stress reactions. The bioavailability of vaporization is 25-50%.

Citation capsule: Choosing a CBD product for anxiety considers concentration, spectrum, and route of administration; broad spectrum preferred by 78% of European consumers eliminates psychoactive risk, and vaporization provides the fastest onset of action within 5-10 minutes (EIHA, 2023).

/where-is-the-best-place-to-store-cbd-oil/

How do CBD and THC interact with psychiatric medications?

CBD and THC are metabolized by cytochrome P450 enzymes, mainly CYP3A4 and CYP2C19, which can alter the levels of other medications. Interactions with psychiatric medications, epilepsy drugs, and benzodiazepines are particularly significant. According to the Food and Drug Administration monograph, CBD shows clinically significant interactions with 139 identified drugs ("CBD Drug Interactions," FDA, 2022).

CBD and SSRIs and SNRIs

CBD inhibits CYP2C19 and CYP3A4, increasing the concentration of escitalopram, sertraline, and fluoxetine by 20-40%. Clinically, this may exacerbate side effects: nausea, sleep disturbances, paradoxical increase in anxiety. In theory, it also increases the risk of serotonin syndrome, especially with CBD at doses above 300 mg. All combinations of SSRIs + CBD require psychiatric supervision.

CBD and benzodiazepines and zolpidem

The most clinically significant interaction is the increase in clobazam concentration by 60-80% through inhibition of CYP2C19, as described in the registration of the Epidiolex preparation. A similar mechanism involves alprazolam, midazolam, and zolpidem. Effects may include increased sedation, respiratory disturbances, and fall risk, especially in older adults.

THC and antipsychotic medications

THC may weaken the effects of antipsychotic medications (quetiapine, olanzapine) and exacerbate positive symptoms in predisposed individuals. In patients with a positive history of psychosis or schizophrenia, THC is contraindicated. CBD, on the other hand, is being studied as an adjunct in schizophrenia due to its anxiolytic and antipsychotic profile.

Interactions with medications for other conditions

Warfarin, antiepileptic drugs (clobazam, valproate), immunosuppressants (tacrolimus), and some chemotherapeutics interact with CBD. Patients with comorbidities should discuss supplementation with their treating physician and possibly monitor drug levels in serum.

Contrary to popular belief that CBD is "natural, therefore safe," its potential for pharmacokinetic interactions is similar to grapefruit, which has long been recognized as a significant warning in pharmacology. Consumers rarely receive this information from product labels.

Citation capsule: CBD shows clinically significant interactions with 139 drugs through inhibition of CYP3A4 and CYP2C19, including a 60-80% increase in clobazam concentration and a 20-40% increase in SSRIs, requiring psychiatric supervision during concurrent supplementation (FDA, 2022).

When is it absolutely necessary to go to a psychiatrist instead of a cannabis shop?

CBD and THC are neither medications nor substitutes for psychiatric care. The decision to start pharmacotherapy or psychotherapy lies with the psychiatrist. According to the European Psychiatric Association, a delay in the diagnosis of anxiety disorders of more than 2 years increases the risk of chronicity and treatment resistance by 54% (Fineberg et al., European Psychiatry, 2019).

Red flags requiring immediate consultation

Signals requiring urgent visits to a psychiatrist (and in extreme cases to the emergency room) include: suicidal thoughts or self-harm, episodes of depersonalization lasting hours, panic attacks with fainting, rapid weight loss, insomnia lasting more than 2 weeks, psychotic episodes (hallucinations, delusions). CBD and THC are not an appropriate first response in any of these scenarios.

Where to seek help in Poland

In Poland, available are: Mental Health Centers (consultation without referral and free of charge), mental health clinics (referral from a primary care physician), private psychiatrists. Telephone support: 116 123 (Adult Helpline), 116 111 (Child and Youth Helpline), 22 484 88 01 (Antidepressant Helpline Forum Against Depression).

The role of CBD as an adjunct, not a substitute

After starting psychiatric treatment and after consultation with a physician, CBD can serve as a complementary role, especially in the waiting phase for the effect of SSRIs or in long-term support for sleep quality. However, one should not discontinue prescribed pharmacotherapy in favor of CBD or reduce doses without consultation. Sudden discontinuation of SSRIs can cause withdrawal syndrome.

Medical marijuana in Poland, legal status 2025

In Poland, medical marijuana has been legal since 2017 and requires a Rpw prescription. Indications include: chronic pain resistant to treatment, spasticity in MS, treatment-resistant epilepsy, nausea after chemotherapy. Anxiety disorders are not a standard reimbursed indication. The monthly cost of medical cannabis ranges from 400 to 1800 PLN depending on the dose and preparation. CBD as a dietary supplement is legal with THC content below 0.3%.

Citation capsule: A delay in the diagnosis of anxiety disorders of more than 2 years increases the risk of chronicity and treatment resistance by 54%; CBD and THC can at most be a supplement, not a substitute for psychiatric consultation (Fineberg et al., European Psychiatry, 2019).

/what-is-ptsd-cbd-as-support-for-post-traumatic-stress-treatment/

What does the safety profile of CBD look like in long-term use?

CBD is considered a substance with a low toxicity profile. The World Health Organization review from 2018 stated that CBD "does not exhibit abuse potential or dependence potential" ("Cannabidiol (CBD) Critical Review Report," WHO, 2018). However, long-term safety at doses above 300 mg daily requires monitoring.

Most common side effects

The most commonly reported adverse effects of CBD include: fatigue, dry mouth, diarrhea, decreased appetite, dizziness. Symptoms usually resolve after 3-7 days of adaptation or dose reduction. In the Epidiolex study in epilepsy, serious adverse effects occurred in 2.1% of patients at doses of 10-20 mg/kg daily.

Risk of hepatotoxicity

CBD at high doses (above 1000 mg daily chronically) may cause elevated liver enzymes ALT and AST. The mechanism involves competition for CYP450 and direct oxidative stress. The risk is particularly significant in combination with valproate or other hepatotoxic drugs. Monitoring liver enzymes every 3-6 months is recommended with long-term use.

CBD during pregnancy and in children

During pregnancy and breastfeeding, CBD is not recommended due to a lack of safety data. In children, the only authorized use is for Dravet syndrome and Lennox-Gastaut syndrome. In anxiety in adolescents, data are preliminary (Berger 2022) and require replication. The young brain maturing until the age of 25 is more sensitive to the effects of cannabinoids.

Risk of misuse and dependence

CBD does not exhibit a dependence profile. In contrast, THC leads to the development of cannabis use disorder (CUD) in about 9% of regular users. In individuals starting use before the age of 18, the risk increases to 17%. In the context of anxiety, dependence is an additional therapeutic burden.

Citation capsule: CBD has a low misuse profile and is recognized by WHO as a safe substance at typical supplemental doses, but doses above 1000 mg daily require monitoring of liver enzymes, and the risk of dependence on THC reaches 9% of regular users (WHO, 2018).

What are the research prospects for CBD and THC in anxiety from 2026 to 2030?

The last 3 years have seen a dramatic increase in the number of registered clinical trials on cannabinoids in psychiatry. According to the ClinicalTrials.gov database, as of April 2026, there are 89 active clinical trials on CBD in anxiety disorders, of which 34 are phase II or III RCTs ("Active trials on CBD and anxiety," ClinicalTrials.gov, 2026). This indicates a significant increase in the credibility of data over the next 5 years.

Phase III CBD in GAD, expected outcomes

Two large Phase III RCTs (MAGNOLIA, HELIOS) are investigating CBD as monotherapy and as an adjunct to SSRIs in GAD, with planned completion in 2027. Doses range from 150-600 mg daily for 12 weeks. If the results are positive, CBD may gain registered drug status for this indication, changing the therapeutic landscape.

Next-generation synthetic cannabinoids

Phase II includes synthetic CBD analogs with higher bioavailability and selectivity for the 5-HT1A receptor. An example is VLS-01 (synthetic CBDV) being studied in GAD. Such molecules may bypass the limitations of natural extracts: batch variability, low bioavailability, drug interactions.

Personalization of therapy, pharmacogenomics

Early pharmacogenomic studies suggest that the response to CBD may depend on variants of the CYP2C19, FAAH, and CNR1 genes. In the future, it may be possible to predict which patients are "CBD responders," analogous to genotyping in SSRI treatment. In 2025, the first study associating the FAAH genotype with anxiety reduction after CBD was published.

Entourage effect, studies of complex extracts

An increasing number of studies test not just CBD itself but full-spectrum extracts and cannabinoid blends with terpenes. The goal is to verify the controversial entourage effect hypothesis, which assumes synergy between components. Preliminary results suggest that linalool, myrcene, and beta-caryophyllene may enhance the anxiolytic effects of CBD.

Citation capsule: As of April 2026, there are 89 active clinical trials on CBD in anxiety disorders, including 34 Phase II or III RCTs, which may significantly change the position of CBD in psychiatry and allow for registration as a drug in GAD and SAD over the next 5 years (ClinicalTrials.gov, 2026).

Frequently Asked Questions

Can CBD replace anxiety medications like escitalopram?

No, CBD does not replace SSRIs or any registered anxiolytics. Clinical evidence for CBD is moderate (Cohen's d = 0.42 in the 2024 meta-analysis), while SSRIs have stronger evidence bases (d = 0.6-0.8) and registration in GAD, SAD, PTSD. CBD may be a supplement after consultation with a psychiatrist. Never discontinue SSRIs on your own due to the risk of withdrawal syndrome (Slee et al., The Lancet, 2019).

How long does CBD take to start working for anxiety?

The acute effect of CBD on anxiety appears 60-90 minutes after sublingual dosing and 5-15 minutes after vaporization. The full effect in chronic use (GAD, SAD) reveals itself after 2-6 weeks of regular supplementation, similar to SSRIs. In Berger's 2022 study, 58% of young patients achieved anxiety reduction after 12 weeks of therapy at 200 mg daily (JAACAP, 2022).

Can I combine CBD with alprazolam or other benzodiazepines?

Combining CBD with benzodiazepines requires psychiatric consultation. CBD inhibits CYP2C19, which increases the concentration of alprazolam, midazolam, and clonazepam by as much as 60-80% (FDA, 2022). Effects may include increased sedation, shallow breathing, and risk of falls. This is not an absolutely contraindicated combination, but it requires monitoring of symptoms by the attending physician ("Drug Interactions Update," FDA, 2022).

Does THC help or harm in panic attacks?

THC has a biphasic effect: doses below 7.5 mg may reduce anxiety, but doses of 10-15 mg and higher in 20-30% of cases induce or exacerbate panic attacks (Childs et al., Drug and Alcohol Dependence, 2017). In individuals predisposed to panic or psychosis, THC is contraindicated. In an acute panic attack, CBD is a safer option than THC, but it does not replace learned breathing techniques or emergency pharmacotherapy.

Is CBD safe for long-term use in anxiety?

Data from studies up to 12 months suggest that CBD at doses up to 300 mg daily is well tolerated. The most common adverse effects are fatigue, dry mouth, and gastrointestinal disturbances. At doses above 600 mg daily, periodic monitoring of liver enzymes ALT/AST is recommended. WHO in its 2018 review recognized CBD as a substance with a low misuse profile and safe in typical supplemental applications (WHO, 2018).

Where in Poland can I get a prescription for medical marijuana due to anxiety?

In Poland, medical marijuana requires a prescription Rpw issued by a doctor (psychiatrist or specialist from another field). Anxiety disorders are not a standard reimbursed indication; doctors sometimes issue prescriptions under "off-label use" for PTSD or treatment-resistant anxiety. The cost is 400-1800 PLN per month. Online specialist consultations (private) cost 250-500 PLN. Legal CBD as a supplement is available without a prescription with THC content below 0.3%.

Summary, what we know, what we don't know, and what next

Research from the last decade, especially 2019-2026, provides moderately strong evidence that CBD at doses of 25-600 mg may reduce acute situational anxiety and support the treatment of chronic anxiety. The strongest data pertains to social phobia, where Crippa showed a 50% reduction in anxiety after 300 mg of CBD. THC has a biphasic response: low doses act anxiolytically, while high doses are anxiogenic. Mechanistically, CBD acts through 5-HT1A, FAAH, GABA-A, and reduces amygdala activity.

At the same time, CBD and THC do not replace psychotherapy or pharmacotherapy. In Poland, where the average wait for a psychiatrist through the NFZ is 3.5 months, and anxiety disorders affect 9.3% of adults, the temptation for "self-medication" is understandable but dangerous. A sensible course of action is: psychiatric and psychological consultation, implementation of recommended therapy, considering CBD as a supplement after discussing with a doctor, especially in the context of interactions with SSRIs and benzodiazepines.

If you are looking for a product to support mental comfort, it is worth starting with broad spectrum products with low concentration, such as SOOL CBD 5% oil, documenting effects in a well-being journal. Remember that in a mental health crisis in Poland, the Helpline 116 123 and 112 are always available.

/kategoria/oleje-cbd/

About the author

Michał Waluk is a cannabis education specialist collaborating with u Bucha. He bases his articles on peer-reviewed publications from PubMed, Cochrane, and ClinicalTrials.gov, emphasizing the quality of evidence and the clinical context of Polish patients.

Last updated: April 23, 2026.